COMPARATIVE STUDY TO EVALUATE QUALITY OF LIFE OF AZILSARTAN AND TELMISARTAN IN PATIENTS OF HYPERTENSION.
Main Article Content
Keywords
Hypertension, Quality of life, Azilsartan, Telmisartan.
Abstract
Background: Hypertension(HTN) is a major cardiovascular disease and is a major worldwide clinical problem. The prevalence of hypertension increases in urban and rural areas. The treatment of hypertension began in the 1960s with oral diuretics. The other modalities of treatment of hypertension are beta – blockers, calcium-channel blockers, alpha receptors blockers, ACE inhibitors and ARBs. Quality of life was assessed by SF -12 questionnaire.
Objective:To compare and evaluate the quality of life of Azilsartan and Telmisartan in patients of hypertension.
Material and Methods: In this prospective, open,parallel group, comparative study, 80 patients of hypertension attending the Cardiology Outpatient Department, Govt. Medical College & Rajindra Hospital,Patiala was recruited. This comparative study was done on 80 patients for 8 weeks.
Quality of Life: In my project of Quality of life, I had taken total 80 patients and the patients were divided into two groups and 40 patients each of Azilsartan and Telmisartan. To assess quality of life questionnaire SF-12 was administered to the patients.
Results: There was significant improvement in the quality of life with Azilsartan than Telmisartan.
Conclusion: Azilsartan was a better choice than Telmisartan because there was greater improvement in all the domains of quality of life.
References
2. Jeffery D. Greenberg, Tiwari A, Rajan M,Miller D, Nataranjan S and Pogach L.Determinants of sustained uncontrolled blood pressure in national cohort of persons with diabetes. AJH 2006; 19:161-69.
3. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Kardiol Pol 2019; 77: 71–159.
4. Soni RK, Porter AC, Lash JP, Unruh ML. Health Related Quality Of Life in Hypertension, CKD & Coexistent Chronic Health Conditions. Adv Chronic Kidney Dis. 2010; 17(4):17-26.
5. Bulpitt CJ, Fletcher AE. The measurement of quality of life in hypertensive patients: a practical approach. Br. J. Clin Pharmacol.1990; 30(3):353-64.
6. Raskeliene V, Babarskiene MR, Macijauskiene J, Seskevicius A. Impact of duration and treatment of arterial hypertension on health-related quality of life. Medicina (Kaunas). 2009; 45(5):405–11.
7. Leonetti G, Comerio G, Cuspidi C. Evaluating quality of life in hypertensive patients. J Cardiovasc Pharmacol. 1994; 23(5):54–8.
8. Weir MR, Prisant LM, Papademetriou V, Weber MA, Adegbile IA, Alemayehu D, et al. Antihypertensive therapy and quality of life. Influence of blood pressure reduction, adverse events, and prior antihypertensive therapy. Am J Hypertens. 1996; 9(9):854–9.
9. Fletcher AE, Bulpitt CJ, Chase DM, Collins WC, Furberg CD, Goggin TK, et al. Quality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine. Hypertension. 1992; 6(1):499–507.
10. Tolerability and quality of life in ARB treated patients. Am J Manag Care.2005; 11(13):S392-4.
11. Yamamoto S, Kawashima T, Kunitake T, Koide S, Fujimoto H. The effects of replacing dihydropyridine calcium-channel blockers with angiotensin II receptor blocker on the quality of life of hypertensive patients. Blood Press Suppl. 2003; 2:22-8.
12. Goodman R, Lanese J, Singson C. Symptom assessment and quality of life in hypertensive patients following modification of antihypertensive therapy to a regimen containing valsartan. J Clin Outcomes Res. 2004; 8:1-14.
13. Varis J, Ruuska M, Johansson J, Kantola I. Antihypertensive treatment with candesartan monotherapy does not improve the Quality of life of finnish hypertensive patients. Int J Clin Trials. 2013; 4: 1-7.
14. Maladkar M, Verma VK, Narsikar KA, Walinjkar RD, Patil WR, Saggu NJS. Triple drug combination of telmisartan, amlodipine and hydrochlorothiazide in the treatment of essential hypertension. Open journal of internal medicine. 2012; 2:67-71.
15. Fujiwara N, Tanaka A, Kawaguchi A, Tago M, Oyama J, Uchida Y et al. Association Between Blood Pressure Lowering and Quality of Life by Treatment of Azilsartan. Int Heart J 2017; 58: 752-761.
16. Weber MA, Bakris GL, Neutel JM, Davidai G, Giles TD. Quality of Life Measured in a Practice-Based Hypertension Trial of an Angiotensin Receptor blocker. J Clin Hypertens. 2003; 5(5):322-9.
17. Tanka A, Node K. Switching from an angiotensin II receptor blocker to azilsartan improved health-related QOL scores beyond sufficient blood pressure-lowering in patients with uncontrolled hypertension. J Hypertens [Internet]. 2018; 36(e327). Availablefrom:https://journals.lww.com/jhypertension/Abstract/2018/10003/A13308_Switching_from_an_angiotensin_II_receptor.1349.aspx?exportImagesToPpt=true#pdf-link
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Ena Bhajni
Assistant Professor, Department of Pharmacology,Maharishi Markandeshwar College of Medical Science & Research, Sadopur, Haryana.
Dr. Balbir Kaur
Associate Professor, Department of Pharmacology, Punjab Institute of Medical Sciences, Jalandhar, Punjab
Dr. Ashish Puri
Associate Professor, Department of Pharmacology, Maharishi Markandeshwar College of Medical Science & Research, Sadopur, Haryana.
Dr. Ashish Kumar
Professor, Department of Medicine, Government Medical College, Patiala, Punjab.